Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NervGen Pharma ( (TSE:NGEN) ) just unveiled an announcement.
NervGen Pharma has reported its Q1 2025 financial results and provided updates on its operational progress. The company completed the last subject visit in the chronic cohort of its Phase 1b/2a clinical study for NVG-291, targeting spinal cord injury, with data expected in early June 2025. Additionally, the FDA has approved an expanded access protocol for NVG-291, allowing treatment use for eligible individuals. The company is also advancing its research activities with NVG-300, showing promising preclinical results in ischemic stroke and SCI. Financially, NervGen reported a cash and investments balance of $14.5 million as of March 31, 2025, with a net cash burn of $4.1 million for the quarter.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing neuro-reparative therapeutics. The company is primarily engaged in the development of treatments for spinal cord injury (SCI) and other nervous system damages, with its lead candidate being NVG-291.
Average Trading Volume: 58,073
Technical Sentiment Signal: Buy
Current Market Cap: C$261.7M
Find detailed analytics on NGEN stock on TipRanks’ Stock Analysis page.